>>Signaling Pathways>> Proteases>> Lipoxygenase>>CAY10583

CAY10583

Catalog No.GC41044

CAY10583은 강력하고 선택적인 완전 류코트리엔 B4 수용체 유형 2(BLT2) 작용제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

CAY10583 Chemical Structure

Cas No.: 862891-27-8

Size 가격 재고 수량
5mg
US$82.00
재고 있음
10mg
US$157.00
재고 있음
25mg
US$371.00
재고 있음
50mg
US$658.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Leukotriene B4 (LTB4) promotes a number of leukocyte functions including aggregation, stimulation of ion fluxes, superoxide anion production, chemotaxis, and chemokinesis. Two G protein-coupled receptors, BLT1 and BLT2 mediate the actions of LTB4. CAY10583 is a potent, selective full agonist for BLT2 with an EC50 value of 20 nM. It does not displace [3H]-leukotriene B4 (LTB4) binding to BLT1 at concentrations >1 µM and activates BLT2 at significantly lower concentrations than LTB4 (EC50 = 170 nM). CAY10583 dose dependently increases intracellular calcium stores and induces ERK phosphorylation in Chinese hamster ovary (CHO) cells expressing BLT2 with no effect on CHO cells expressing BLT1.[1] 

Reference:
[1]. Iizuka, Y., Yokomizo, T., Terawaki, K., et al. Characterization of a mouse second leukotriene B4 receptor, mBLT2. BLT2-dependent ERK activation and cell migration of primary mouse keratinocytes. The Journal of Biological Chemisty 280(26), 24816-24823 (2005).

리뷰

Review for CAY10583

Average Rating: 5 ★★★★★ (Based on Reviews and 5 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CAY10583

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.